Clinically useful monoclonal antibodies in treatment
- Correspondence to: Dr E Drewe, Clinical Immunology Unit, Queens Medical Centre, Nottingham NG7 2UH, UK; Liz.Drewe{at}Nottingham.AC.UK
- Accepted 6 July 2001
Abstract
Monoclonal antibodies have been used in clinical diagnosis for many years but it is only now that these agents are being licensed for clinical treatments. This review will focus on UK licensed monoclonal antibodies highlighting their clinical benefits, limitations, and side effects.
- monoclonal antibodies
- recombinant technology
- chimaeric antibodies
- tumour necrosis factor α
- Crohn's disease
- rheumatoid arthritis
- CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone
- dsDNA, double stranded DNA
- IL, interleukin
- PTCA, percutaneous transluminal coronary angioplasty
- RA, rheumatoid arthritis
- RSV, respiratory syncitial virus
- TNF-α
- tumour necrosis factor α
